Search 

Headquartered in Geneva, Switzerland, NovImmune is a life science enterprise with a proprietary next-generation antibody drug discovery platform and expertise in advancing drug candidates from bench to bedside. The Company is applying its capabilities to realize a vision of generating drugs that provide more robust benefit to patients by attacking the cause rather than symptoms of disease. NovImmune has established a balanced pipeline of first- and best-in-class pre-clinical and clinical drug candidates with a mix of both clinically validated and novel targets.

§  CHF 182M raised from high net worth individuals, private and corporate venture funds

§  In 2009, received the European Biotechnica Award

§  In 2010, established Genentech/Roche partnership for NI-1401, anti-IL-17 drug candidate

§  In 2011, received Orphan Drug designation in Europe and the USA for, and EUR 6 million FP7 grant from the European Commission for development of NI-0501 for HLH

§  In 2012, filing to initiate important clinical studies including the first Phase II study for NI-0501 in HLH, and first-in-man study for leading anti-TLR4 drug candidate, NI-0101

§  Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates

§  Potential to independently bring selected drugs to the market for focused applications

Numab is a Swiss biotech company focusing on the discovery and development of therapeutic antibodies. Numab is a young company lead by a Management with proven track record in the biotech industry.

Numab applies a high-throughput selection system that increases the antibody discovery success rates by magnitudes and allows to efficiently identify best-in-class and/or first in class antibodies. The discovery engine is particularly well suited to detect antibodies against unconventional targets such as multi-spanning transmembrane proteins (e.g. GPCRs or ion channels).

Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, however, also applies its breakthrough technology to discover highly potent antibodies on behalf of its partners in the pharmaceutical industry.

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis.

The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of Ireland’s leading academic institution with a core focus on immunology research. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers. The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.

The Company is supported by an international venture consortium including Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and Enterprise Ireland. Further information is available at http://www.opsona.com/.

ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. 

Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration.   Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase1. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration. Two recent papers in NatureMedicine and CancerCELL stablished proof of concept data that support the use of LSD1 inhibitors in acute myeloid leukemia. Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in leukemia and the other in Huntington disease. Phase I/IIa studies are expected to start in early 2013.

In Oncology, we also develop new non invasive early diagnostics tools. Our first product GynEC®-DX consists on a new set of markers for triage in endometrial cancer from uterine aspirates.

Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to individual patients.

The company, which is a spin out from Oxford University, has a patent-protected and validated platform for discovering proteins that are novel chemosensitivity markers for specific drugs.

OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech companies.

Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can sometimes hamper the companion biomarker business model.

The company has secured initial funding via a $5 million equity investment from Quintiles.

OCB's management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue, Professor of Cancer Biology at the University of Oxford.